Rufinamide

Phase 3

Eisai (ESALY)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Lennox-Gastaut Syndrome

View Full Landscape

Drug Information

Target Indication

Lennox-Gastaut Syndrome

Clinical Trial

NCT01405053

Last updated: 12/23/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA1/16/2007

Inovelon

Inovelon is indicated as adjunctive therapy in the treatment of seizures associated with Lennox Gastaut syndrome in patients 4 years of age and older.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

ESALY

Eisai

Healthcare•North America•NASDAQ

Related Pipeline

Eperisone hydrochloride and Diclofenac sodiumPhase 3

Acute Musculoskeletal Spasm Due to Low Back Pain

T-614Phase 3

Rheumatoid Arthritis

Eszopiclone 1 mgPhase 3

Primary Insomnia

TeprenonePhase 3

Gastric or Duodenal Ulcers Caused by Low-dose Aspirin

ClevudinePhase 3

Chronic Hepatitis B

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts